Novo Nordisk has said its weight loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly’s rival medicines Mounjaro and Zepbound in a real-world comparison of overweight and obese patients with cardiovascular disease but not diabetes.
Reuters reports that while this was not a randomised controlled trial, Novo said the findings – from the real-world STEER study – provide evidence that the heart-protective benefits of Wegovy and its main ingredient semaglutide may not be the same for all GLP-1 drugs, such as tirzepatide, the active ingredient in Zepbound and Mounjaro.
Compared with tirzepatide, a 2.4mg dose of Wegovy showed a significant 57% greater risk reduction for heart attack, stroke and cardiovascular-related death or death from any cause while on treatment with no gaps of more than 30 days, the Danish drugmaker said.
The actual number of major adverse heart events was low for both drugs – 15, or 0.1%, of patients on Wegovy and 39, or 0.4%, of tirzepatide patients. The average follow-up duration was 3.8 months for the Wegovy group and 4.3 months for tirzepatide.
The data, gathered from more than 21 000 patients and presented at the European Society of Cardiology (ESC) meeting in Madrid this past weekend, also showed a 29% reduction in heart risk and death from any cause in Wegovy users compared with tirzepatide users, regardless of any gaps in their treatment.
The findings could provide a boost for Novo, which has been losing US market share to Zepbound since becoming Europe’s most valuable company last year on booming sales of Wegovy.
The US Food and Drug Administration (FDA) is reviewing a high-dose oral version of Wegovy for potential approval later this year. Novo said it helped overweight or obese adults lose 15% of their weight in a late-stage trial.
Real-world studies cannot prove cause and effect the way randomised clinical trials do. Other limitations of the study include the short follow-up duration.
See more from MedicalBrief archives:
UK approves weight-loss jab for heart attacks, stroke
Weight loss drug approved for heart disease prevention